Acceding to the recommendation of an independent data monitoring committee (DMC), Eli Lilly and Co. said it was terminating the phase III ACCELERATE study of evacetrapib (formerly LY2484595) in high-risk atherosclerotic cardiovascular disease (CVD) for lack of efficacy, bringing the program to an abrupt end.